PUK14 FACTORS INFLUENCING THE ROUTE OF ADMINISTRATION FOR EPOETIN TREATMENT AMONG U.S. HEMODIALYSIS PATIENTS  by Thamer, M et al.
417Abstracts
PUK13
PREDICTORS OF MEDICATION ADHERENCE AND
ASSOCIATED HEALTH CARE COSTS IN AN OLDER
POPULATION WITH DETRUSOR OVERACTIVITY: A
LONGITUDINAL COHORT STUDY
Balkrishnan R1, Bhosle M1, Camacho F2,Anderson RT2
1Ohio State University, Columbus, OH, USA; 2Wake Forest University
School of Medicine, Winston Salem, NC, USA
OBJECTIVE: The cost of treating detrusor overactivity (overac-
tive bladder) is high (12.0 billion dollars in the United States in
2000). It is important to understand predictors of adherence to
therapy with detrusor control medications and to determine the
relationships between adherence and health care service utiliza-
tion in older adults (aged 65 years or older) with detrusor 
overactivity. This study examined the relationship between self-
reported health status data, subsequent antidiabetic medication
adherence, and health care service utilization in older adults with
detrusor overactivity in a managed care setting. METHODS:
This was a longitudinal cohort study of older adults in the south-
eastern United States with detrusor overactivity who completed
a health status assessment, used muscarinic antagonist medica-
tions, and were enrolled in a health maintenance organization
(HMO) continuously for one to ﬁve years. Demographic, 
clinical, and utilization-related economic variables were also
retrieved from the administrative claims data of the patients’
HMO. Prescription reﬁll patterns were used to measure adher-
ence. Associations were examined with a sequential, mixed-
model, regression approach. RESULTS: A total of 176 patients
were included. Increased age and lower number of prescribed
medications during the year prior to enrollment in a Medicare
HMO were independently associated with decreased muscarinic
antagonist medication possession ratios (MPRs) after enroll-
ment. After controlling for type of medication therapy and other
variables, increased muscarinic antagonist MPR remained the
strongest predictor of decreased total annual health care costs
(6.7% decrease in annual costs with every 10% increase in MPR;
P < 0.001). CONCLUSIONS: This study found strong associa-
tions between decreased muscarinic antagonist medication
adherence and increased health care service utilization in older
adults with detrusor overactivity in a managed care setting.
Health status assessments completed at time of enrollment had
the potential to identify enrollees with higher risk for both non-
adherent behaviors and poor health-related outcomes.
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OBJECTIVES: Few studies have examined the factors associated
with the choice of route of administration of epoetin therapy
among anemic hemodialysis patients. We conducted a cross-
sectional study using data from the Centers for Medicare &
Medicaid Services’ End-Stage Renal Disease (ESRD) Clinical 
Performance Measures Project (CPM) to examine route of
administration and anemia management strategies associated
with receiving subcutaneous (SC) or intravenous (IV) epoetin.
METHODS: Information was collected from 7630 patients
receiving hemodialysis in October to December, 2000. Unad-
justed associations were examined using t- and chi-square tests.
Adjusted associations were estimated using logistic regression
analyses. RESULTS: Use of SC route of administration varies
widely across the United States. White, wealthier, incident to
dialysis patients residing in the Midwest and West, and receiv-
ing dialysis in larger, hospital-based, not-for-proﬁt independent
facilities were more likely to receive SC epoetin. After control-
ling for patient sociodemographics and clinical history in a 
multivariate analysis, geography, proﬁt status, and chain mem-
bership were the most signiﬁcant predictors of route of admin-
istration. Hemodialysis patients in the Midwest and West were
ﬁve and more than four times as likely compared to those in the
Northeast (OR = 4.94, CI 3.80, 6.42 and OR = 4.34, CI 3.30,
5.70, respectively), and patients receiving dialysis from the only
large not-for-proﬁt chain were almost 6 times as likely compared
to the largest for-proﬁt chain (OR = 5.88, CI 3.90, 8.85) to
receive SC epoetin. CONCLUSIONS: Study ﬁndings indicate
that clinical decision-making regarding route of administration
for epoetin therapy appears to be inﬂuenced strongly by facility
ownership and ESRD network in which a patient resides. Given
the similar efﬁcacy but signiﬁcantly reduced epoetin dose asso-
ciated with SC administration, these ﬁndings suggest an enor-
mous lost opportunity for more efﬁcient use of resources in the
Medicare program.
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IMPACTS OF IMPLEMENTING CASE PAYMENT SYSEM TO
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FREQUENCIES AND EXPENDITURE IN KOREA
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OBJECTIVE: To assess the impacts of implementing case
payment system (CPS) to Medical Aid (MA) hemodialysis
patients on dialysis frequencies and expenditure. METHODS:
Fifty-eight clinics and 35 tertiary care hospitals were identiﬁed
as having a minimum of 10 hemodialysis patients for each 
of MA and Medical Insurance (MI) programs, who received
hemodialysis from the same dialysis facilities for both of July,
2001 and July, 2002. From these facilities, 2167 MA and 2928
MI patients were identiﬁed as study subjects. Using electronic
claims data, changes in the total number of monthly treatments
and charges for outpatient hemodialysis treatments to each
patient after the introduction of the CPS were compared between
MA and MI patients. Multiple regression analyses were per-
formed to examine the independent impact of the CPS on the
utilization and expenditure of dialysis treatments among MA
patients. RESULTS: There was signiﬁcant decrease in total
charges of hemodialysis treatments for MA patients by 3.4% (p
< 0.05), whereas signiﬁcant increase was observed for MI
patients by 2.5% (p < 0.05). For both MA and MI patients, the
frequency of monthly hemodialysis treatments were signiﬁcantly
increased, 5.5% (from 12.1 to 12.7) and 7.8% (from 11.6 to
12.5) increase for MA and MI patients, respectively. However, 
a multivariate regression analysis results showed that there was
no signiﬁcant difference in the changes in the total number of
monthly hemodialysis treatments between MA and MI patients
after implementing CPS. Another regression model, regressing on
the changes in the monthly claims of dialysis treatments, showed
a signiﬁcant negative coefﬁcients for the MA (beta = -70,725, 
p < 0.05). CONCLUSION: The result of signiﬁcant decrease in
total charges for hemodialysis treatments among MA patients as
compared to MI patients suggest that there was cost reduction
in MA program after the CPS.
